Loading
The 2020 American guideline update that told doctors to test every treatment-eligible patient with metastatic pancreatic cancer for inherited BRCA changes, mismatch repair deficiency and TRK fusions, because each now had a drug attached.
ASCO convened an Expert Panel and systematic review to update its metastatic pancreatic cancer guideline for therapy after first-line treatment. One randomised trial of olaparib versus placebo (POLO), one report on phase 1 and 2 studies of larotrectinib and one on entrectinib met the inclusion criteria. New or updated recommendations cover germline and somatic testing for microsatellite instability or mismatch repair deficiency, BRCA mutations and TRK alterations in all treatment-eligible patients, to select patients for pembrolizumab, olaparib, larotrectinib or entrectinib, or for trials. The panel continued to endorse the 2018 recommendations for second-line chemotherapy (gemcitabine plus nab-paclitaxel after FOLFIRINOX; fluorouracil plus nanoliposomal irinotecan after gemcitabine-based therapy) and for palliative care and follow-up.
The document that made biomarker testing part of routine pancreatic cancer care in the United States; the 2018 version it built on fixed the second-line chemotherapy sequence still used in most guidelines.
Shares Thierry Conroy, POLO, Eileen M. O'Reilly, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question and the tag pancreatic-evidence.
Shares POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, Germline BRCA mutation (gBRCA), Germline vs somatic mutations, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question and the tag pancreatic-evidence.
Shares POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, Germline BRCA mutation (gBRCA), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares American Society of Clinical Oncology (ASCO), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Journal of Clinical Oncology, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Germline BRCA mutation (gBRCA), Germline vs somatic mutations, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Thierry Conroy, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.